Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025

Prilenia Therapeutics and Ferrer announced the presentation of their planned pivotal Phase 3 study of pridopidine in Amyotrophic Lateral Sclerosis (AL...
Home/KnloSights/Clinical Trial Updates/Prilenia and Ferrer Announce Phase 3 ALS Study of Pridopidine at NEALS 2025